Procter & Gamble is buying wellness brand Thorne from L Catterton for $3.8 billion in cash, a deal announced August 4 that lands alongside a fiscal 2027 earnings outlook weighed down by roughly $1 billion in new cost headwinds. The all-cash transaction, expected to close in the fourth quarter of 2026, gives P&G entry into a clinically backed supplement category and comes as management guided core EPS to $6.89 to $7.11, implying growth of just 0% to 3%. The company cited roughly $1 billion in after-tax commodity, energy, and transportation costs, plus higher net interest expense, lower non-operating income, and unfavorable currency, as a combined $0.56 per share drag. P&G returned $10.2 billion in dividends and $5.0 billion in share repurchases in fiscal 2026 and plans roughly the same for fiscal 2027, while shares trade near $144, about 21 times fiscal 2026 core earnings.
Procter & Gamble CompanyFiscal 2027 guidance disappoints with 0-3% EPS growth and $1B cost headwinds.
Acquired by P&G for $3.8B cash, providing a premium exit.
Selling Thorne for $3.8B, but impact on L Catterton's portfolio unclear.
